Peter Lamb

EVP, Scientific Strategy at Exelixis

Peter Lamb, Ph.D., is Executive Vice President, Scientific Strategy at Exelixis, a role he has held since December 2022. For more than 15 years, from January 2007 to December 2022, in addition to serving in a variety of positions of increasing responsibility in the company’s Drug Discovery organization, Dr. Lamb was Exelixis’ Chief Scientific Officer. Specifically, he served as Executive Vice President, Discovery Research and Chief Scientific Officer from September 2009 to February 2016, as Senior Vice President, Discovery Research and Chief Scientific Officer from January 2007 until September 2009, as Vice President, Discovery Pharmacology from December 2003 until January 2007 and as Senior Director, Molecular Pharmacology and Structural Biology from October 2000 until December 2003. Prior to joining Exelixis, from June 1992 until September 2000, Dr. Lamb held positions of increasing responsibility at Ligand Pharmaceuticals, a pharmaceutical company, most recently serving as Director of Transcription Research. Dr. Lamb has held post-doctoral research fellowships at the Carnegie Institution, Department of Embryology, with Dr. S.L. McKnight and the University of Oxford with Dr. N.J. Proudfoot, working in the field of gene regulation. He has authored numerous articles in the fields of gene expression, signal transduction and oncology, and is an author on multiple issued and pending U.S. patents. He has a Ph.D. in Molecular Biology from the ICRF/University of London and a B.A. in Biochemistry from the University of Cambridge.


Previous companies

Ligand Pharmaceuticals logo


  • EVP, Scientific Strategy

    Current role

  • EVP, Scientific Strategy & Chief Scientific Officer

View in org chart